Forecast

The analysts' average price target is €10.36 (+143.19%). The median is €10.36 (+143.19%).

Buy	5
Hold	2
Sell	0

News Go to news feed

Champions Oncology presents eight poster studies at AACR annual meeting

Champions Oncology will present eight poster presentations at the 2026 AACR annual meeting in San Diego, showcasing research on KRAS‑mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody‑drug conjugates and CAR‑T therapies. The studies use patient‑derived models combined with molecular, functional and phenotypic data to identify biomarkers, therapy responses and resistance mechanisms. The company highlights collaboration talks during the conference; the stock is trading near its 52‑week low, with analyst targets up to $12. » More on de.investing.com
Champions Oncology reports 11% revenue growth and improves gross margin to 52%

Champions Oncology reported Q2 2025 revenue of USD 15m (+11% yoy) and an improved gross margin of 52% (prior year 45%). Operating income was USD 185,000, adjusted EBITDA about USD 800,000; cash balance USD 8.5m with no debt. The stock rose about 16% in after-hours trading following the release. The company is investing in its data platform, reviewing external financing options for subsidiary Corelia, and again aims for full-year revenue growth and a positive adjusted EBITDA. » More on de.investing.com
Champions Oncology to release quarterly results on 15 December

Champions Oncology will publish its quarterly results for the period ended 31 October 2025 on 15 December 2025. One analyst expects EPS of 0.000 USD (prior year 0.050 USD) and revenue of about 14.0 million USD (+4.08% versus 13.5 million USD). For the current fiscal year, EPS is forecast at 0.150 USD (prior year 0.330 USD) and revenue at 59.9 million USD. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2014, Champions Oncology has already paid €0.0404 in dividends. The last payout was in June 2014.

Financials

In the last quarter, Champions Oncology had revenue of €11.8M and net profit of -€621.55K

(EUR)	Apr 2026	YoY
Revenue	11.8M	8.12%
Gross profit	5.99M	33.45%
Net profit	-621.55K	61.64%
EBITDA	-148.35K	89.30%

Fundamentals

Metric	Value
Market capitalization	€59.12M
Number of shares	13.89M
52-week high/low	€7.54 - €4.17
Dividends	No
Beta	0.41
P/E ratio	-61.62
PEG ratio	0.37
P/B ratio	17.31
P/S ratio	1.15

Company profile

Champions Oncology, Inc. entwickelt und vertreibt Technologielösungen und Produkte zur Personalisierung der Entwicklung und Anwendung von Krebsmedikamenten in den Vereinigten Staaten. Seine Tumorgraft-Technologieplattform ist ein Ansatz zur Personalisierung der Krebsbehandlung, der auf der Implantation menschlicher Tumore in immungeschwächte Mäuse beruht. Das Unternehmen bietet mit seiner Tumorgraft-Technologieplattform eine personalisierte Krebsbehandlung an, die auf der Implantation menschlicher Tumore in immungeschwächte Mäuse beruht. Darüber hinaus bietet es translationale Onkologielösungen an, die seine Technologieplattform nutzen, um Pharma- und Biotechnologieunternehmen bei der Arzneimittelentwicklung zu unterstützen. Das Unternehmen vermarktet seine Produkte über das Internet, Mundpropaganda und Außendienstmitarbeiter bei Patienten und Ärzten. Das Unternehmen war früher als Champions Biotechnology, Inc. bekannt und änderte im April 2011 seinen Namen in Champions Oncology, Inc. Champions Oncology, Inc. wurde 1985 gegründet und hat seinen Hauptsitz in Hackensack, New Jersey.

Name	Champions Oncology
CEO	Robert Brainin
Headquarters	Hackensack, nj USA
Website	championsoncology.com
Sector	Consumer Staples
Industry	Food Products
IPO	02/02/2007
Employees	214